drugset / Trial / NCT05027295

Accelerated Corneal Collagen Crosslinking for Keratoconus and Ectasia Using Pulse or Continuous UV-A Light

NCT05027295

Phase 3 Unknown 170 enrolled Cornea and Laser Eye Institute
RandomizedParallel-groupOpen-labelTreatment

Summary

Corneal collagen crosslinking has been demonstrated as an effective method of reducing progression of both keratoconus and post-refractive corneal ectasia, as well as decreasing the steepness of the cornea in these pathologies. Performing an accelerated CXL procedure with pulsed UVA light may increase the oxygenation of the cornea, which may improve the crosslinking efficacy.

Timeline

Start
2021-07-30
Primary completion
2025-07
Completion
2025-07

Drugs

EvaluationDrugModalityDoseRoute
Comparator Riboflavin Other / unclassified